1. Therapeutic efficacy of ¹⁸⁸Re-liposome in a C26 murine colon carcinoma solid tumor model

   • Ya-Jen Chang
   • Chin-Wei Hsu
   • Te-Wei Lee

   PRECLINICAL STUDIES 09 December 2012 Pages: 801 - 811

   

2. Functional and molecular characterization of kinin B₁ and B₂ receptors in human bladder cancer: implication of the PI3Kγ pathway

   • V. Sgnaolin
   • T. C. B. Pereira
   • M. M. Campos

   PRECLINICAL STUDIES 07 December 2012 Pages: 812 - 822

   

3. Sonic hedgehog antagonists induce cell death in acute myeloid leukemia cells with the presence of lipopolysaccharides, tumor necrosis factor-α, or interferons

   • Frank Leigh Lu
   • Ching-Chia Yu
   • Jean Lu

   PRECLINICAL STUDIES 13 December 2012 Pages: 823 - 832

   

4. LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

   • S. Betty Yan
   • Victoria L. Peek
   • Richard A. Walgren

   PRECLINICAL STUDIES Open access 29 December 2012 Pages: 833 - 844

   

5. Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer

   • Peter M. Wilson
   • Melissa J. LaBonte
   • Robert D. Ladner

   PRECLINICAL STUDIES 09 January 2013 Pages: 845 - 857

   

6. Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells

   • Angel Mauricio Castro-Gamero
   • Kleiton Silva Borges
   • Luiz Gonzaga Tone

   PRECLINICAL STUDIES 09 January 2013 Pages: 858 - 870

   

7. Preclinical antitumor activity of a nanoparticulate SN38

   • Mazin F. Al-kasspooles
   • Stephen K. Williamson
   • Katherine F. Roby

   PRECLINICAL STUDIES 09 January 2013 Pages: 871 - 880

   

8. Monitoring the effects of bevacizumab beyond progression in a murine colorectal cancer model: a functional imaging approach

   • L. Heijmen
   • C. J. A. Punt
   • H. W. M. van Laarhoven

   PRECLINICAL STUDIES 17 January 2013 Pages: 881 - 890

   

9. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib

   • Grace K. Dy
   • Jeffrey R. Infante
   • Howard A. Burris III

   PHASE I STUDIES 08 November 2012 Pages: 891 - 899

   

10. A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors

    • Thierry Lesimple
    • Julien Edeline
    • Larisa Reyderman

    PHASE I STUDIES 11 November 2012 Pages: 900 - 909

    

11. A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer

    • Takayuki Yoshino
    • Kentaro Yamazaki
    • Atsushi Ohtsu

    PHASE I STUDIES Open access 20 November 2012 Pages: 910 - 917

    

12. A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors

    • David S. Hong
    • Jennifer Hsing Choe
    • Razelle Kurzrock

    PHASE I STUDIES 20 November 2012 Pages: 918 - 926

    

13. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors

    • Jeffrey R. Infante
    • Silvia Novello
    • Alex A. Adjei

    PHASE I STUDIES 22 November 2012 Pages: 927 - 936

    

14. Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma

    • Andrew Poklepovic
    • Leena Youseffian
    • John D. Roberts

    PHASE I STUDIES 13 January 2013 Pages: 937 - 942

    

15. A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study

    • Noelle K. LoConte
    • Kyle D. Holen
    • Sam J. Lubner

    PHASE I STUDIES 21 December 2012 Pages: 943 - 948

    

16. Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery

    • Nigel Bundred
    • Janis Gardovskis
    • J. Michael Dixon

    PHASE I STUDIES 13 January 2013 Pages: 949 - 958

    

17. Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors

    • F. E. Stuurman
    • E. E. Voest
    • A. Hendlisz

    PHASE I STUDIES 24 January 2013 Pages: 959 - 966

    

18. A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies

    • Aung Naing
    • Roger Cohen
    • Alex A. Adjei

    PHASE I STUDIES 30 January 2013 Pages: 967 - 973

19. A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors

    • Sunil Sharma
    • Joachim Beck
    • H. Miles Prince

    PHASE I STUDIES 02 February 2013 Pages: 974 - 985

    

20. First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

    • Glen J. Weiss
    • Joseph Chao
    • Yun Yen

    PHASE II STUDIES 09 February 2013 Pages: 986 - 1000

    

21. Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer

    • Robert Jones
    • Jacqueline Vuky
    • Gary Hudes

    PHASE II STUDIES 18 January 2013 Pages: 1001 - 1007

    

22. A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium

    • Srikala S. Sridhar
    • Mary J. Mackenzie
    • Malcolm J. Moore

    PHASE II STUDIES 26 January 2013 Pages: 1008 - 1015

    

23. A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors

    • Darren R. Feldman
    • Lawrence H. Einhorn
    • Robert J. Motzer

    PHASE II STUDIES 17 February 2013 Pages: 1016 - 1022

    

24. Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)

    • Harry P. Erba
    • Hamid Sayar
    • Michael Andreeff

    PHASE II STUDIES 10 February 2013 Pages: 1023 - 1034

    

25. Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study

    • Luca Moscetti
    • Fabrizio Nelli
    • Enzo M. Ruggeri

    PHASE II STUDIES 17 February 2013 Pages: 1035 - 1043

    

26. A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer

    • Robert Dreicer
    • Jorge Garcia
    • Derek Raghavan

    PHASE II STUDIES 24 February 2013 Pages: 1044 - 1050

    

27. Potential factors correlating to the PMDA’s decision to waive Japanese Phase 2 and 3 studies for oncology drugs New Drug Application in Japan

    • Keitaro Nakajima
    • Koji Chiba
    • Toshio Suwa

    PHASE III STUDIES 19 December 2012 Pages: 1051 - 1055

    

28. Effect of selection of QTc formula on eligibility of cancer patients for phase I clinical trials

    • Mitesh J. Borad
    • Arundhati D. Soman
    • Daniel D. Von Hoff

    SHORT REPORT 16 December 2012 Pages: 1056 - 1065

    

29. Opioid growth factor (OGF) for hepatoblastoma: a novel non-toxic treatment

    • Moshe Rogosnitzky
    • Milton J. Finegold
    • Ian S. Zagon

    SHORT REPORT 30 December 2012 Pages: 1066 - 1070

30. Ipilimumab associated hepatitis: imaging and clinicopathologic findings

    • Kyung Won Kim
    • Nikhil H. Ramaiya
    • Nageatte Ibrahim

    SHORT REPORT 14 February 2013 Pages: 1071 - 1077

    

31. Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis

    • Viswanath Reddy Belum
    • Shenhong Wu
    • Mario E. Lacouture

    REVIEW 23 May 2013 Pages: 1078 - 1086

    

32. Cardiac glycosides in cancer therapy: from preclinical investigations towards clinical trials

    • M. Slingerland
    • C. Cerella
    • H. Gelderblom

    REVIEW 10 June 2013 Pages: 1087 - 1094

    

33. Erratum to: Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma

    • Andrew Poklepovic
    • Leena E. Youssefian
    • John D. Roberts

    Erratum 06 July 2013 Pages: 1095 - 1095